• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Acessa Health touts Medicaid win

Acessa Health touts Medicaid win

February 13, 2018 By Fink Densford

Acessa Health

Acessa Health said today that 32 state Medicaid programs now provide access to the company’s Acessa procedure designed to treat uterine fibroids using radiofrequency ablation.

The Acessa procedure, utilizing the Acessa system, is designed as a uterine sparing alternative to hysterectomy. The procedure can treat most sizes and locations of fibroids, including those in the uterine walls, and requires no suturing or cutting of the uterine tissue, the company said.

The decision from the state-run Medicaid programs adds an additional 20 million women who are eligible to receive treatment with the Acessa system, bringing the total to over 70 million.

“The expansion of Medicaid coverage for the Acessa procedure represents another significant step forward in terms of recognizing the medical necessity of this procedure as well as increasing the number of options women have as alternatives to hysterectomy. We are committed to improving awareness of all available treatment pathways for women with symptomatic uterine fibroids,” Acessa Health market access VP Ryan Graver said in a press release.

Last September, Acessa Health touted data from a 10-year systematic review and meta-analysis of its Acessa system, touting reduced blood loss, hospitalization time and readmission rates.

Filed Under: Business/Financial News, Women's Health Tagged With: acessahealth

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy